Target intelligence / Profile preview

Antibody deficiency

Molecular classification
Other
01

Overview

Antibody deficiency refers to a group of disorders characterized by insufficient quantity or function of antibodies—proteins produced by B cells that play an essential role in the immune response. This condition can be primary (genetic/intrinsic) or secondary (acquired due to other diseases or treatments). Primary forms include common variable immunodeficiency (CVID), X-linked agammaglobulinemia, selective IgA deficiency, hyper-IgM syndromes, and others. Patients typically experience frequent and/or severe infections due to impaired ability to fight off pathogens. Some may also develop autoimmune symptoms or chronic inflammation. The underlying causes vary widely and may involve defects at different stages of B cell development or function; many cases have complex genetic backgrounds involving multiple genes[1][2][3][4]. Antibody deficiencies are not single molecules nor receptors, but instead represent heterogeneous clinical syndromes resulting from various defects in humoral immunity. As such, "antibody deficiency" is not considered a therapeutic target like an enzyme or receptor would be—it is instead the result of dysfunctions in several possible molecular targets within the immune system. Because this entry does not refer to one specific molecule/receptor/protein/gene but rather describes an umbrella category for multiple related conditions with diverse etiologies and mechanisms—and because it cannot be directly targeted by drugs—the entry should be flagged as incorrect for use as a canonical therapeutic target[1][2]. “Predominantly antibody deficiencies...are heterogeneous group[s]...characterized by dysfunctional antibody production...”[2] “Primary antibody deficiency...is the name given to a number of different conditions...”[1] “Antibodies are produced by B cells...Each B cell makes [a] different antibody...”[3] In summary: “Antibody deficiency” is not itself a molecule/receptor/target suitable for structured drug-target information extraction; it represents various disorders caused by failure(s) at multiple points along the humoral immune pathway.

Other names
Primary antibody deficiencyPredominantly antibody deficiencyPADSpecific antibody deficiencyAgammaglobulinemia (as a subtype)Common variable immunodeficiency (CVID, as a subtype)Selective IgA deficiency (as a subtype)IgG subclass deficiency (as a subtype)Hyper IgM syndrome (as a subtype)
02

Biological functions

Immune response
03

Disease associations

InfectionAutoimmunityInflammationOther (e.g., gastrointestinal disease, allergy, malignancy)

Beyond the preview

Go deeper on Antibody deficiency.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Antibody deficiency.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call